ArticleJournal of tissue engineering and regenerative medicine2025
The Chorioallantoic Membrane as a Platform for Developing Vascularized Cell Macroencapsulation Devices.
Article in Journal of tissue engineering and regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cell macroencapsulation devices (CMD) offer a promising solution for organ function replacement by shielding implanted cells from the host immune system while allowing the exchange of nutrients and waste products. Developing efficient CMD necessitates optimizing vascular integration, membrane permeability, and cellular functionality using robust preclinical models. In this study, we adapted the chick chorioallantoic membrane (CAM) model to develop and evaluate CMD. Methods: Semipermeable membranes were integrated into the CAM, with vascularization modulated through growth factors and extracellular matrix manipulation. Human kidney tubular epithelial cells were cultured on these vascularized membranes to assess cell viability, polarization, and functionality, including selective transport and barrier integrity. Results: The membranes integrated successfully into the CAM and supported functional vascularization, demonstrating selective permeability by facilitating the exchange of low-molecular-weight compounds while preventing the infiltration of larger proteins and cells, thereby creating an immune-isolated environment. Kidney tubular epithelial cells remained viable, polarized, and functionally active, showcasing selective compound transport and robust barrier integrity. Conclusion: These findings underscore the CAM model's utility in evaluating vascular integration, membrane permeability, and epithelial cell functionality, all critical parameters for CMD development. The CAM model provides a rapid, cost-effective platform for CMD assessment, significantly accelerating their development and potential clinical translation. This approach holds particular promise for applications targeting kidney diseases characterized by compromised transport functions, offering a pathway toward more effective therapeutic solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.